Nagahiro Saijo

TL;DR: Accumulation of data with respect to the expression profiles of PCNSL specimens, clinicopathological data, susceptibility to treatment, and outcome will provide information for identifying optimal therapeutic modalities for individual patients and novel therapeutic targets.

TL;DR: An improved method for disaggregation of solid tumors increased the yield of single cells and more than 10 anticancer drugs could be tested in 94 of 168 specimens, and cloning efficiencies varied markedly from specimen to specimen.

TL;DR: A large number of patients die from recurrent disease and the limitations of treatment in terms of effectiveness and tolerability have driven researchers to develop new strategies to reduce treatment-related toxicity and improve the survival rates of cancer patients.

TL;DR: The administration of LAK cells and/or human rIL-2 restored the cytotoxicity of spleen lymphocytes against YAC-1 and syngeneic B- 16 melanoma cells in ACNU-treated mice, and these treatments partially suppressed the increased numbers of artificial pulmonary metastases of B-16 melanomacells.

TL;DR: This work explores the portfolio of clinical trials being conducted in locally advanced NSCLC by North American cooperative oncology groups as well as ongoing trials in Europe and Japan and focuses on radiation dose escalation using image-guided radiation therapy aswell as newer cytotoxic agents.